MRS. NATALIE M HILL MSN, WHNP-BC
Prescription History 1417354721
Nurse Practitioner - Women's Health in Madison, IN


Quality Rating: 77.27 out of 100 score

NPI Status: Active since December 02, 2014

Contact Information

1373 E STATE ROAD 62 STE 2F
MADISON, IN
ZIP 47250
Phone: (812) 801-0856
Fax: (812) 801-0771

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MRS. NATALIE M HILL MSN, WHNP-BC, an active Women's Health specialist practicing in Madison, IN. Our medical registry currently tracks 16 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 446 documented patient claims. Among these therapy options, the most frequently utilized medication is Alendronate Sodium, which accounts for 66 claims alone.


Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 66
30-Day Fills 183.1
Days Supply 5,490
IN State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills108.5
Peer Average Days Supply3,195
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 37.5% more claims than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $798.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.09

State Avg Cost Per Claim

$10.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Clobetasol Propionate

Generic Formulation: Clobetasol PropionateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 51
30-Day Fills 51.7
Days Supply 1,035
IN State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills42.7
Peer Average Days Supply1,088
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 30.8% more claims than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,261.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.74

State Avg Cost Per Claim

$68.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A derivative of PREDNISOLONE with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than FLUOCINONIDE, it is used topically in treatment of PSORIASIS but may cause marked adrenocortical suppression.

Therapeutic Applications

This medication is used to treat a variety of skin conditions (such as eczema, psoriasis, dermatitis, allergies, rash). Clobetasol reduces the swelling, itching, and redness that can occur in these types of conditions. This medication is a very strong (super-high-potency) corticosteroid.

Estradiol

Generic Formulation: EstradiolSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 61
30-Day Fills 142.2
Days Supply 4,115
IN State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills65.0
Peer Average Days Supply1,930
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 117.9% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,320.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$54.44

State Avg Cost Per Claim

$55.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Estradiol (Once Weekly)

Generic Formulation: EstradiolSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 20
30-Day Fills 27.2
Days Supply 784
IN State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills23.3
Peer Average Days Supply667
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,568.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$78.43

State Avg Cost Per Claim

$88.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Fluconazole

Generic Formulation: FluconazoleSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.9
Days Supply 109
IN State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills24.5
Peer Average Days Supply248
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $106.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.26

State Avg Cost Per Claim

$12.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.

Therapeutic Applications

Fluconazole is used to treat vaginal yeast infections. It works by stopping the growth of common types of vaginal yeast (fungus). This medication belongs to a class of drugs called azole antifungals.

Forteo

Generic Formulation: TeriparatideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 378
IN State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.4
Peer Average Days Supply664
Conservative Utilization

This provider writes prescriptions for this formulation 40.9% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $58,382.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,490.93

State Avg Cost Per Claim

$4,426.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A polypeptide that consists of the 1-34 amino-acid fragment of human PARATHYROID HORMONE, the biologically active N-terminal region. The acetate form is given by intravenous infusion in the differential diagnosis of HYPOPARATHYROIDISM and PSEUDOHYPOPARATHYROIDISM. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

Therapeutic Applications

Teriparatide is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. It is similar to a natural hormone in your body (parathyroid hormone). It works by increasing bone mass and strength. This effect helps to decrease the risk of getting a fracture. This medication is not recommended for use in children or young adults whose bones are still growing.

Medroxyprogesterone Acetate

Generic Formulation: Medroxyprogesterone AcetateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 55
30-Day Fills 119.0
Days Supply 3,309
IN State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills35.7
Peer Average Days Supply968
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 161.9% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $470.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.56

State Avg Cost Per Claim

$30.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic progestin that is derived from 17-hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by intramuscular injection and has also been used to treat breast and endometrial neoplasms.

Therapeutic Applications

This medication is used to prevent pregnancy. Medroxyprogesterone is like a natural hormone made by the body. Using this medication does not protect you or your partner against sexually transmitted diseases (such as HIV, gonorrhea, chlamydia).

Megestrol Acetate

Generic Formulation: Megestrol AcetateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 13
30-Day Fills 21.0
Days Supply 600
IN State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills20.2
Peer Average Days Supply523
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $173.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.33

State Avg Cost Per Claim

$73.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Megestrol acetate is a progestogen with actions and uses similar to those of the progestogens in general. It also has anti-androgenic properties. It is given by mouth in the palliative treatment or as an adjunct to other therapy in endometrial carcinoma and in breast cancer. Megestrol acetate has been approved to treat anorexia and cachexia. (From Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

Therapeutic Applications

Megestrol is used to treat loss of appetite and weight loss in people with AIDS. Improving your appetite and gaining weight may help you feel better and be more active. Megestrol is similar to a natural substance made by the body called progesterone.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 210
IN State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills67.8
Peer Average Days Supply1,835
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.3% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,294.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$156.89

State Avg Cost Per Claim

$614.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Oxybutynin Chloride Er

Generic Formulation: Oxybutynin ChlorideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 17
30-Day Fills 43.0
Days Supply 1,290
IN State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills64.4
Peer Average Days Supply1,851
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,536.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$90.40

State Avg Cost Per Claim

$41.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This is a long-acting form of oxybutynin that is used to treat overactive bladder and urinary conditions. It relaxes the muscles in the bladder to help decrease problems of urgency and frequent urination. Oxybutynin belongs to a class of drugs known as antispasmodics. This medication is also used to treat children 6 years of age and older who have an overactive bladder due to certain nerve disorders (such as spina bifida).

Premarin

Generic Formulation: Estrogens, ConjugatedSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 22
30-Day Fills 53.4
Days Supply 1,580
IN State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills33.2
Peer Average Days Supply979
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 29.4% more claims than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,508.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$477.66

State Avg Cost Per Claim

$406.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate.

Therapeutic Applications

This medication is a female hormone. It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment. Certain estrogen products may also be used by men and women to treat cancers (certain types of prostate cancer, breast cancer that has spread to other parts of the body) and by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure).

Progesterone

Generic Formulation: Progesterone, MicronizedSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 15
30-Day Fills 43.0
Days Supply 1,290
IN State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills59.1
Peer Average Days Supply1,751
Conservative Utilization

This provider writes prescriptions for this formulation 48.3% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,125.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$75.06

State Avg Cost Per Claim

$63.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat infertility in women who do not make enough of a certain natural hormone called progesterone. This hormone is needed to maintain pregnancy. This medication is also used to restore menstrual cycles in women whose cycles have stopped. Progesterone is needed to keep menstrual periods regular.

Raloxifene Hcl

Generic Formulation: Raloxifene HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 18
30-Day Fills 53.0
Days Supply 1,590
IN State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills46.2
Peer Average Days Supply1,354
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,316.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$73.12

State Avg Cost Per Claim

$98.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Therapeutic Applications

Raloxifene is used by women to prevent and treat bone loss (osteoporosis) after menopause. It slows down bone loss and helps to keep bones strong, making them less likely to break. Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive breast cancer) after menopause. Raloxifene is not an estrogen hormone, but it acts like estrogen in some parts of the body, like your bones. In other parts of the body (uterus and breasts), raloxifene acts like an estrogen blocker. It does not relieve menopause symptoms such as hot flashes. Raloxifene belongs to a class of drugs known as selective estrogen receptor modulators-SERMs. This medication should not be used before menopause. It should not be used to prevent heart disease.

Triamcinolone Acetonide

Generic Formulation: Triamcinolone AcetonideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 23
30-Day Fills 25.0
Days Supply 467
IN State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills39.7
Peer Average Days Supply943
Conservative Utilization

This provider writes prescriptions for this formulation 34.3% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $112.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.88

State Avg Cost Per Claim

$11.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.

Therapeutic Applications

This medication is used in a variety of conditions such as allergic disorders, arthritis, gout, blood diseases, breathing problems, certain cancers, eye diseases, intestinal disorders, collagen and skin diseases. Talk to your doctor about the risks and benefits of triamcinolone, especially if it is to be injected near your spine (epidural). Rare but serious side effects may occur with epidural use. Triamcinolone is known as a corticosteroid hormone (glucocorticoid). It works by decreasing your body's immune response to these diseases and reduces symptoms such as swelling.

Venlafaxine Hcl Er

Generic Formulation: Venlafaxine HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 21
30-Day Fills 45.5
Days Supply 1,365
IN State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills69.8
Peer Average Days Supply2,047
Conservative Utilization

This provider writes prescriptions for this formulation 38.2% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $337.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.09

State Avg Cost Per Claim

$32.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Venlafaxine is used to treat depression, anxiety, panic attacks, and social anxiety disorder (social phobia). It may improve your mood and energy level and may help restore your interest in daily living. It may also decrease fear, anxiety, unwanted thoughts, and the number of panic attacks. Venlafaxine is known as a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by helping to restore the balance of certain natural substances (serotonin and norepinephrine) in the brain.

Yuvafem

Generic Formulation: EstradiolSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 13
30-Day Fills 36.7
Days Supply 1,101
IN State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills35.9
Peer Average Days Supply1,050
Conservative Utilization

This provider writes prescriptions for this formulation 35.0% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,369.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$182.23

State Avg Cost Per Claim

$139.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MRS. NATALIE M HILL MSN, WHNP-BC provides transparency into local medical care patterns within Madison, IN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Women's Health** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.